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Background – Interleukin (IL)-2 stimulates antitumour immunity and is successfully used for the treatment of
different neoplasias.
Hypothesis/Objectives – Canarypox virus locally expressing feline IL-2 is safe and can be used to treat equine
sarcoids.
Animals – Twenty horses of different breeds with a median age of eight years (interquartile range 6.0–13.3
years) and a total number of 59 sarcoids were included in the study.
Methods – In this prospective clinical trial, sarcoids were injected twice seven days apart, with a recombinant
canarypox virus expressing feline IL-2. Complete blood counts (CBC) and fibrinogen levels were measured before
treatment and on days 1, 2, 7 and 8.
Results – Complete regression was achieved in eight horses (40%) and partial regression in two horses (10%).
No change in sarcoid size was observed in two horses (10%) and the disease progressed in five horses (25%).
Sarcoids of three horses (15%) showed initial response followed by tumour growth. There were no significant
changes in CBC and fibrinogen levels after either injection. One horse developed a mild fever the day after each
injection, which subsided without treatment the following day.
Conclusions – Treatment of equine sarcoids with recombinant canarypox virus expressing feline IL-2 seems to
be a safe therapy option. Although the expression of IL-2 after vector injection and its biological activity in horses
were not proven in this study, the treatment resulted in regression and partial regression in 50% of the cases.
Further studies are necessary to verify these findings and to establish a treatment protocol.
Introduction
Equine sarcoids are a locally invasive fibroblastic neo-
plasia, which represent 90% of skin tumours in horses.
They occur in six different forms and at specific predilec-
tion sites throughout the body. Sarcoids show a high
recurrence rate after treatment, and failure of treatment
often is followed by more aggressive tumour growth.
Numerous treatment options have been published since
the first description of equine sarcoids in 1936,1 yet none
have been universally successful.2–7 No licensed medica-
tion for the treatment of equine sarcoids is currently avail-
able and, therefore, human medicine or medication
authorized for other species have to be used off-label.
There is a considerable risk for the treating veterinarian
while using some medicines, such as chemotherapeu-
tics, as a result of their carcinogenic qualities. These cir-
cumstances have fuelled the search for safe and
successful treatment options against equine sarcoids.
A novel focus of cancer research in human medicine is
cancer immunology and the question of how the host’s
immune system can be stimulated to recognize and tar-
get tumour cells. Interleukin (IL)-2 is one of the key cytoki-
nes with stimulating effects on the immune system, and
has been approved for systemic treatment of metastatic
renal cell carcinomas and metastatic melanoma in
humans.8 As a growth factor, it stimulates the prolifera-
tion of cytotoxic T cells, T-helper (TH) cells (TH-1, TH-2
and TH-17), natural killer cells and lymphokine-activated
killer cells, all of which contribute to antitumour
responses.8 Activation of lymphokine-activated killer cells
by equine IL-2 has been demonstrated in horses9 and is
known to mediate tumour regression in humans and
horses.9–14
IL-2 treatment has been used in human medicine since
1985. A wide variety of different application regimes have
been tested. One of the major concerns of high-dose,
recombinant, systemically injected IL-2 therapy in human
cancer patients is severe adverse effects, including chills,
fever and hypotension. These symptoms are not induced
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by the IL-2 itself and instead by the IL-2-promoted eleva-
tion of pyrogenic cytokines, such as tumour necrosis fac-
tor (TNF)a.15 Local application systems have been tested,
such as direct subcutaneous or intratumoural injection of
low-dose recombinant IL-2, the use of viral (e.g. canary-
pox virus) or bacterial vectors or plasmid-based delivery
systems, to avoid systemic adverse reactions.16 The
canarypox vector is a promising delivery system as its
safety is well-established and antivector immunity does
not interfere with the efficacy of subsequent injections.
This delivery system is, therefore, successfully used in
human patients with cutaneous metastasis of mela-
noma.17 Locally applied IL-2 has been used in veterinary
medicine to prevent the recurrence of feline fibrosarco-
mas after surgical resection.18,19 Feline fibrosarcomas
show similarities to equine sarcoids and have a high
recurrence rate. Injections into the tumour bed of feline
fibrosarcomas with canary poxvirus expressing feline IL-2
(Oncept IL-2, drug approval no. EU/2/13/150/001, Merial;
Lyon, France) reduced the recurrence rate after surgical
resection.18 The published genetic sequences of feline
and equine IL-2 show an homogeneity of 76%.
We investigated the safety of the application of canary-
pox virus expressing feline IL-2 in healthy horses in this
prospective clinical trial. Thereafter, we evaluated the effi-
cacy of the product to treat equine sarcoids.
Methods and materials
Ethics approval and consent to participate
The study was approved by the State Office of Health and Social
Affairs Berlin (LaGeSo), sampling of control horses was approved
(ref. no. G0220/18). The owners gave permission to include their
horses in the study.
Safety study
Four clinic-owned horses (three mares, one gelding) with unremark-
able clinical and dermatological examinations were included in the
study. They were aged between five and 25 years (mean 16  8.9
years) with a mean body weight of 489  87 kg. Two of the horses
were Arabians and two were Standardbreds. Each horse was injected
twice, seven days apart, with Oncept IL-2 (lyophilizate + manufac-
turer’s solvent) and with the manufacturer’s solvent only as a control
at two different sites. Injections were performed subcutaneously on
the same side of the neck, ≥8 cm apart. The lyophilizate contained
feline IL-2 recombinant canarypox virus (vCP1338) ≥ 106.0 EAID50
(ELISA infectious dose 50%) as the active substance, with sucrose,
collagen hydrolysate, casein hydrolysate, sodium chloride, disodium
phosphate dihydrate and potassium dihydrogen phosphate as excipi-
ents. Water was the solvent for injections. Clinical and dermatological
examinations were performed before treatment [Day (D)0] and
repeated daily (D1–D14). Skin biopsies were taken with a 4 mm
biopsy punch (Dermal Biopsy Punch, WDT; Garbsen, Germany). They
were formalin-fixed, bisected and paraffin-embedded. Paraffin sec-
tions were cut and stained with haematoxylin & eosin. A board-certi-
fied pathologist analysed the tissue sections for any aberrations. Skin
biopsy 1 was taken on D0 from healthy, untreated skin. The first sub-
cutaneous injections of Oncept IL-2 (Location A1) and solvent only
(control, Location B1) were performed on D0 after the first biopsy
was taken. The second subcutaneous injections with Oncept IL-2
(Location A2) and solvent only (Location B2) were performed on D7.
Biopsies 2 and 3 were collected from each injection site five days
after injection. All biopsy wounds were closed with staples.
In addition, CBC and fibrinogen levels were determined before the
first treatment (D0) and on D1, D2, D5, D7, D8 and D12. The CBC
were performed from ethylenediaminetetraacetic acid blood samples
(VetScan HM 5, Abaxis Europe GmbH; Griesheim, Germany); fibrino-
gen levels were measured in heparinized blood samples (Coagulome-
ter nach Schnitger und Gross, ABW Medizin und Technik GmbH;
Lemgo, Germany).
Clinical trial
Horses. Twenty client-owned horses with clinically suspected sar-
coids were recruited from the patient pool for this study. Horses
were excluded from the study if they had systemic disease, sarcoids
exceeding 10 x 10 cm, or if the clients were unable to document the
development of the sarcoids after discharge from the clinic. Age, sex
and breed of the horses enrolled can be seen in Table 1. Patient his-
tory and clinical examination results were obtained on admission to
the clinic.
Sarcoids. The number, location, type and size of the sarcoids in all
horses were recorded before the initiation of treatment. Sarcoids
were confirmed in all cases by histological examination of a 2 mm
punch biopsy taken from one sarcoid per case on the day of first
treatment. Biopsy wounds were left untreated. Sarcoid type and
locations are listed in Table 2; the location regions are depicted in
Table 2.
Treatment
A maximum dose of three vials per horse (equalling a maximum of
three sarcoids treated) were used. If horses had more than three sar-
coids, the owners could choose which three sarcoids should be trea-
ted. Horses were sedated with detomidine (20–40 µg/kg BW
intravenous, Cepesedan, CP Pharma; Burgdorf, Germany) and butor-
phanol (0.1 mg/kg BW i.v., Dolorex, MSD Animal Health; Unter-
schleißheim, Germany) if necessary. The surrounding area of the
sarcoid was clipped as necessary. The skin was disinfected with alco-
hol swabs before injection. Horses received intratumoural treatment
on D1 and D7 with a dose of ≥106.0 EAID50 Oncept IL-2/mL (= one
commercially available vial). Horses were observed for approximately
15 min post-treatment for any immediate local or generalized
adverse reactions.
Additional examinations
Vital signs were obtained daily for eight days. The CBC (VetScan
HM5, Abaxis Europe GmbH) and fibrinogen levels (Coagulometer
nach Schnitger und Gross, ABW Medizin und Technik GmbH) were
determined in-house before treatment and on D1, D2, D7 and D8. All
sarcoids were photographed and measured (width and length) by
two independent observers with a Vernier caliper on arrival and again
before discharge from the clinic. The mean value of the measures
was calculated each time. The horses were discharged from the
clinic one day after the second treatment. Horse owners pho-
tographed and measured sarcoids at home once a week until eight
weeks after the last treatment and then once a month until the end
of the observation period (ranging from 22 to 40 months).
Statistics
Statistical analyses were carried out using SPSS STATISTICS v24 (IBM;
Endicott, NY, USA). Descriptions included frequencies for categorical
variables and means, medians, standard deviations and interquartile
ranges for continuous data. Outcomes were categorized as binary
variables. The first group comprised sarcoids that fully regressed
(complete regression, CR) or partially responded by ≥50% (partial
response, PR). The second group included those that were not
reduced at all or by <50% (stable disease, SD), showed tumour
growth (progression of disease, PD) or recurrence of tumour (RT)
(Figure 1).20
The binary variables were used as dependent variable in two multi-
variable mixed logistic regression models. The SD group was used as
a reference group. The one sarcoid of fibroblastic type was excluded
from the model. Some horses had more than one sarcoid and, there-
fore, animal IDs were included as random factors in the model, while
location (reference: head), size (reference: 40–80 cm2), type
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(reference: occult) and treatment (reference: no treatment) served as
fixed factors. One model was fitted for all sarcoids and a second
model included only those sarcoids that were treated in order to addi-
tionally investigate the influence of follow-up time. All factors were
included in the model in a single step, and no selection process was
carried out. Interactions between variables could not be included in
the models owing to the small number of observations. Odds ratios
(OR) and 95% confidence intervals (95% CI) are presented in the
text. The significance level was set at P < 0.05 (Table S1).
Results
Safety study
All horses were clinically and dermatologically healthy
before treatment (D0). Horse 3 showed a mild leukopenia
on D0 (4.8 x 103/µL; reference range 5–10 x 103/µL).
None of the horses showed any pathological changes in
the clinical examination after the first or second
Table 1. Animals in this study, types and number of sarcoids, and results.
Breed Age (years) Sex Number of sarcoids Types of sarcoids Result
1 Warmblood 8 Gelding 2 O, V CR
2 Warmblood 7 Mare 3 O, V RT
3 Warmblood 5 Gelding 6 O, V, N CR
4 Pony 11 Mare 1 N RT
5 Pony 6 Gelding 1 O PR
6 Noriker 10 Gelding 11 V CR
7 Warmblood 17 Mare 1 N CR
8 Warmblood 8 Gelding 1 O PD
9 Warmblood 18 Mare 3 V, N PR
10 Warmblood 8 Gelding 1 V SD
11 Quarter horse 2 Gelding 1 O PD
12 Haflinger 22 Gelding 4 N PD
13 Warmblood 6 Gelding 2 O, N CR
14 Quarter horse 10 Mare 4 V ST
15 Pony 7 Mare 2 O, N CR
16 Pony 6 Gelding 3 N PD
17 Warmblood 20 Mare 2 O, N PD
18 Tinker 11 Gelding 13 V, N, F CR
19 Warmblood 4 Gelding 1 N RT
20 Warmblood 14 Mare 3 O, V CR
F fibroblastic; O occult sarcoid; V verrucous; CR complete regression PD progression of disease; PR partial regression; RT recurrence of tumour;
SD stable disease
Table 2. Locations and types of sarcoids found on the horses in this study
Location Number Type of sarcoid Number
Region 1 Head 18 Occult 14
Region 2 Torso 23 Verrucous 24
Region 3 Genital region /perineum 13 Fibroblastic 1
Region 4 Legs 5 Mixed 0
Nodular 20
Malevolent 0
Total 59 Total 59
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treatment. Horse 4 had a mild leukocytosis after the first
treatment (D2; 10.9 x 103/µL; reference range 5–
10 x 103/µL), which resolved by D5. The CBC and fibrino-
gen levels remained within the reference ranges in all
horses after the second treatment. Horse 2 showed mild
oedema at all four injection sites on D2 which resolved
the next day. None of the other horses showed reactions
at the injection sites. Horse 3 showed mild signs of
inflammation (mild swelling and exudation) at all biopsy
sites. In conclusion, none of the horses showed
significant adverse effects after two treatments with
Oncept IL-2.
The main findings of the histopathological examination
were moderate to severe, diffuse perivascular lympho-
plasmacellular dermatitis and panniculitis with mild
oedema at all sites treated (A1 and A2). Biopsy A2 from
Horse 4 additionally showed a moderate infiltration of
eosinophilic granulocytes. Histopathological examinations
of biopsy 1 (D0, before treatment) and control locations
(B1 and B2) yielded no abnormal findings.







Figure 1. Example pictures of equine sarcoid and responses to recombinant canarypox virus expressing feline interleukin (IL)-2 treatment. PD,
progressive disease; PR, partial response; CR, complete regression.
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Clinical trial
Twenty horses with a total number of 59 sarcoids com-
pleted treatment and finished the trial. The number of sar-
coids per horse ranged from one to 13. Nine of 59
sarcoids had received other treatments previously with-
out success. One horse developed an upper airway infec-
tion after the first injection and was subsequently
withdrawn before completing the trial. The mean obser-
vation period was 30 months (range 22–40 months).
A total of 38 sarcoids were treated in 20 horses, and
one sarcoid of each horse was biopsied without signs of
inflammation or complications of wound healing at the
biopsy site. Treatment with Oncept IL-2 was well-toler-
ated by all horses. None of the horses showed haemato-
logical parameters outside the physiological range at any
time point. Furthermore, all measured blood parameters
were within the reference ranges before and one day
after treatment. One horse developed mild fever the day
after the first treatment which subsided the following day
without requiring therapy.
Complete regression of all sarcoids, including those
that had not been treated, was achieved in eight horses
(40%) and PR in two horses (10%). Sarcoids did not
change in size in two horses (10%), and the disease pro-
gressed in five horses (25%). Sarcoids showed response
in three horses (15%) initially and then progressed again.
A total of 25% (n = 5) of the sarcoids injected with IL-2
progressed, whereas 10% (n = 2) did not change in size.
In 10% (n = 2) of treated sarcoids PR was achieved in
10% (n = 2) of sarcoids treated and CR in 40%. A total of
15% (n = 3) of the treated sarcoids responded to treat-
ment initially and then progressed again.
When the sarcoids that were not injected are included,
then 16.95% of sarcoids (n = 10) progressed, 3.95%
(n = 2) remained stable in size and PR was achieved in
3.95% (n = 2). A majority of 67.8% (n = 40) of sarcoids
showed CR and 8.47 % (n = 5) of sarcoids recurred. Of
the 67.8% of sarcoids that showed CR, regression
started after a median time of 30.4  5.4 weeks (Table 3).
Treatment proved to have a major impact on the proba-
bility of a reduction of ≥50% (P < 0.001) in the multivari-
able mixed logistic regression model including all
sarcoids. Neither location (P = 0.334), size (P = 0.828)
nor type (P = 0.342) played a major role. The classification
of the model reached 100% and, thus, all observations
were classified correctly by the model. This is a sign of
possible overfitting of the model. The covariance analysis
revealed that 88% of the variance was due to variance
between horses. This means that individual effects
played a major role in the probability of a reduction of
50% of the sarcoids treated.
The multivariable mixed logistic regression model
including only sarcoids treated showed that the follow-up
time point of six months had the highest impact on the
probability of a reduction of ≥50% (P = 0.066). The OR of
66.3 was extremely high and also had a large 95% CI
(0.660–6648.1). Reduction was not strongly related to
sarcoid location, with legs having the highest chance of
reduction [OR 3.3 (95% CI: 0–27.690) compared to head]
and core having the lowest chance [OR 0.085 (95% CI: 0–
16.1) compared to head]. Sarcoids of the nodular type
had the lowest chance of reduction, while verrucous sar-
coids were more often reduced by >50%; the longer the
observation period, the smaller the chance for reduction
by >50%. The classification of the model reached 100%,
so that all observations were classified correctly by the
model. More than 90% of the variance was the result of
variance between horses.
Discussion
Only mild local adverse effects and mild leukocytosis
occurred in one horse after subcutaneous injection of
Oncept IL-2 in the initial safety study with four healthy
horses. In the prospective clinical study with 20 horses
none of the horses with equine sarcoids showed signifi-
cant adverse effects after intratumoural treatment. The
canarypox vector generally has been found to be a safe
delivery system. Systemic adverse effects after Oncept-
IL 2 application have occurred rarely in cats and included
transient apathy and fever.19
The canarypox vector has been used in horses previ-
ously and shows high biosafety because it is nonreplica-
tive in mammalians, and genetically and physically
stable.21 It is, however, not certain whether the vector
Table 3. Results for 59 sarcoids from 20 horses (38 sarcoids from 20 horses were treated with recombinant poxviruses expressing feline inter-

















CR PR SD PD RT
Results in paents Results of treated sarcoids Results of all sarcoids (treated and untreated)
In Results in patients, the least responsive tumor of a patient was considered the overall result for evaluation.
PD, Progressive disease; SD, stable disease; PR, Partial regression; CR, Complete regression; RT, recurrence of tumor.
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designed for cats actually induces expression of IL-2 in
horses. Further in-depth studies on the effects of feline
IL-2 on the equine immune system are needed.
Short- and long-term adverse effects of local treatment
with human IL-2 also have been described in horses.
They varied from tenderness and erythema at the injec-
tion site to slight oedema and localized swelling.9 The
combination of cisplatin and human IL-2, however,
showed less severe adverse effects than generally seen
after treatment with Bacillus Calmette–Guerin (BCG) or
repeated cisplatin injections.9 Additional advantages of
Oncept IL-2 treatments are that the drug is safe to handle
for humans due to the low biological activity of feline IL-2
in humans,22 and that it is a licensed veterinary product in
Europe.
A reduction in tumour size or complete resolution of
the tumour after treatment with Oncept IL-2 occurred in
50% of the injected and 68% of all sarcoids in the present
clinical study. Note that complete resolution was defined
as no visible signs of tumour and/or skin alterations, and
that biopsies were not repeated to confirm the resolution
of the sarcoid. Better treatment results in horses with
more than one sarcoid have been reported in the litera-
ture9 with concomitant tumour rejection and/or systemic
immunity after IL-2 therapy as possible explanations. It is
possible that a systemic effect is induced by feline IL-2,
as described for other immunostimulating treatments and
cryosurgery.23 One study showed that the odds of treat-
ment failure were significantly lower for a sarcoid on a
patient that received concurrent immunostimulating treat-
ment (cryosurgery, BCG vaccine injection or imiquimod
application). This would suggest that the immune system
plays a considerable role in sarcoid treatment.23 The influ-
ence of the horses’ immune system in the aetiology of
equine sarcoids is not yet completely understood and
there might be differences in systemic immune reactions
in horses with multiple sarcoids that lead to a changed
responsiveness to IL-2 in these horses. Further studies
are necessary to examine whether local intratumoural
injections of Oncept IL-2 or a systemic parenteral applica-
tion of IL-2 are more beneficial.
It also is possible that horses showed spontaneous
remission during the study, as has been reported in equine
sarcoids.24 One major limitation of the present study is,
therefore, the missing untreated control group. The inclu-
sion of a negative control group was initially planned. All
horses in this study were client-owned and placebo treat-
ment, especially after performing a biopsy, resulted in low
owner compliance. Therefore, no negative control group
was included in the study. Two previous studies showed
tumour size reductions or resolution in untreated control
groups of 14%25 and 16%.26. In another study, sponta-
neous remission was observed in ≤62% of horses during
an observation period of five to seven years.27
A previous study on local treatment of equine sarcoids
with human IL-2 reported a >50% size reduction or com-
plete tumour regression after six months in four of 11
(36%) cases (IL-2 treatment alone intratumourally for five
days, high dose), five of 10 (50%) cases (IL-2 treatment
alone intratumourally for ten days, low dose) and in nine
of 15 (60%) cases (IL-2 treatment combined with cis-
platin).9 Sarcoid types were comparable between the
study mentioned above and our study. A reason for the
slight difference in results could be the use of feline IL-2
and the different treatment regimes. The human IL-2
used in the other study9 shows a homology with equine
IL-2 of 72%, whereas feline IL-2 used in our study shows
a slightly greater homology of 76%.
One disadvantage of the treatment with Oncept IL-2
was the long delay observed between the first injection
and the beginning of tumour remission in the present
study. Of the 68% of sarcoids that did show remission
after 23 months, remission started after a median time of
30.4  5.4 weeks. It is, therefore, not possible to say
with certainty that remission was a consequence of the
treatment as different ways and lag times of tumour
regression after IL-2 treatment have been described in
human patients and ruminants. An immediate regression
has been described in which the tumour resolves within a
few days. This is probably due to reduced blood flow to
the tumour and subsequen necrosis.28,29 A slower
regression (up to one year) was observed in bovine ocular
squamous cell carcinoma30,31 and equine sarcoids.9 In
the latter study, histological changes in tumours 10–15
days after the last IL-2 treatment revealed a lymphocytic-
plasma cellular infiltration that is seen as a late-change
phenomenon.9
Oncept IL-2 is used in cats to prevent the recurrence of
fibrosarcomas after surgical removal, and six treatments
in a seven day interval are indicated.19 The dosage and
the seven day treatment interval for this pilot study were
in accordance with the regime used in cats. However,
more than two treatments may increase the efficacy in
equine patients, and further examinations are necessary
to establish the best treatment regime in horses.
In summary, in this clinical pilot study, the treatment of
equine sarcoids with canarypox virus locally expressing
IL-2 was easy and safe for both user and horse. Equine
sarcoids injected with canarypox virus expressing feline
IL-2 showed a reduction in tumour size or a complete
remission of the tumour in 50% of cases. Further studies
are necessary to research vector and feline IL-2 effects in
horses, establish an optimal treatment regime for equines
and verify the results in a larger population of patients.
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Resume
Contexte – L’interleukine (IL)-2 stimule l’immunite anti-tumorale et est efficacement utilisee pour le traite-
ment de differentes neoplasies.
Hypotheses/Objectifs – Canarypoxvirus exprimant localement IL-2 felin est sûr et peut être utilise pour
traiter les sarco€ıdes equins.
Sujets – Vingt chevaux de differentes races avec un âge median de huit ans (ecart interquartille de 6.0-
13.3 ans) et un nombre total de 59 sarco€ıdes ont ete inclus dans l’etude.
Methodes – Dans cette etude clinique prospective, les sarco€ıdes ont ete injectes deux fois a sept jours
d’intervalle avec un canarypoxvirus recombinant exprimant IL-2 felin. Une formule sanguine (CBC) et les
taux de fibrinogenes ont ete mesures avant traitement et a jours 1, 3, 7 et 8.
Resultats – Une regression complete a ete obtenue pour huit chevaux (40%) et une regression partielle
pour deux chevaux (10%). Aucun changement de taille des sarco€ıdes n’a ete observe pour deux chevaux
(10%) et la maladie s’est aggravee pour cinq chevaux (25%). Les sarco€ıdes de trois chevaux (15%) ont
montre une reponse initiale puis une croissance de la tumeur. Il n’y avait pas de changement significatif
dans le CBC et les taux de fibrinogenes apres chacune des injections. Un cheval a developpe une fievre
moderee le jour apres chaque injection, qui disparaissait sans traitement le jour suivant.
Conclusions – Le traitement des sarco€ıdes equins avec canarypoxvirus exprimant IL-2 felin semble être
une option therapeutique sure. Bien que l’expression d’IL-2 apres injection du vecteur et son activite biolo-
gique chez les chevaux n’aient pas ete prouvees dans cette etude, le traitement resultaient en une
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regression et une regression partielle dans 50% des cas. D’autres etudes sont necessaires pour verifier
ces donnees et pour etablir un protocole therapeutique.
Resumen
Introduccion – la interleuquina 2 (IL-2) estimula la inmunidad antitumoral y se utiliza con exito para el trata-
miento de diferentes neoplasias.
Hipotesis/Objetivos – El poxvirus de canarios que expresa localmente IL-2 felina es seguro y puede
usarse para tratar sarcoides equinos.
Animales – se incluyeron en el estudio veinte caballos de diferentes razas con una mediana de edad de
ocho a~nos (rango intercuartılico 6,0-13,3 a~nos) y un total de 59 sarcoides.
Metodos – en este ensayo clınico prospectivo, se inyectaron sarcoides dos veces con siete dıas de dife-
rencia, con un poxvirus de canarios recombinante que expresaba IL-2 felina. Se midieron los recuentos san-
guıneos completos (CBC) y los niveles de fibrinogeno antes del tratamiento y en los dıas 1, 2, 7 y 8.
Resultados – se logro una regresion completa en ocho caballos (40%) y una regresion parcial en dos caba-
llos (10%). No se observo ningun cambio en el tama~no del sarcoide en dos caballos (10%) y la enfermedad
progreso en cinco caballos (25%). Los sarcoides de tres caballos (15%) mostraron una respuesta inicial
seguida de crecimiento tumoral. No hubo cambios significativos en los niveles de CBC y fibrinogeno
despues de cualquiera de las inyecciones. Un caballo desarrollo una fiebre leve al dıa siguiente de cada
inyeccion, que remitio sin tratamiento al dıa siguiente.
Conclusiones – El tratamiento de los sarcoides equinos con el poxvirus de canarios recombinante que
expresa IL-2 felina parece ser una opcion terapeutica segura. Aunque la expresion de IL-2 despues de la
inyeccion del vector y su actividad biologica en caballos no se probaron en este estudio, el tratamiento
resulto en regresion y regresion parcial en el 50% de los casos. Se necesitan mas estudios para verificar
estos hallazgos y establecer un protocolo de tratamiento.
Zusammenfassung
Hintergrund – Interleukin (IL)-2 stimuliert die Antitumor Immunit€at und wird erfolgreich zur Behandlung
verschiedener Neoplasien eingesetzt.
Hypothese/Ziele – Das Kanarienpoxvirus, welches lokal felines IL-2 exprimiert ist sicher und kann verwen-
det werden, um equine Sarkoide zu behandeln.
Tiere – Es wurden zwanzig Pferde verschiedener Rassen mit einem medianen Alter von acht Jahren (Inter-
quartilsabstand 6,0-13,3 Jahre) und insgesamt 59 Sarkoide in die Studie aufgenommen.
Methoden – Eine v€ollige Remission wurde bei acht Pferden (40%) erzielt und eine partiale Remission bei
zwei Pferden (10%). Es konnte bei zwei Pferden keine Ver€anderung der Sarkoidgr€oße beobachtet werden
(10%) und bei f€unf Pferden verlief die Erkrankung progressiv (25%). Die Sarkoide von drei Pferden (15%)
zeigten anfangs eine Verbesserung, gefolgt von vermehrtem Tumorwachstum. Es gab nach der jeweiligen
Injektion keine signifikanten Ver€anderungen bei Blutbild und Fibrinogenwerten. Ein Pferd hatte am Tag
nach jeder Injektion ein mildes Fieber, welches ohne Behandlung am darauffolgenden Tag wieder ver-
schwand.
Schlussfolgerungen – Eine Behandlung equiner Sarkoide mit rekombinantem Poxvirus, welches felines
IL-2 exprimiert, scheint eine sichere Therapieoption darzustellen. Obwohl die Exprimierung von IL-2 nach
einer Vektorinjektion und seine biologische Aktivit€at bei Pferden in dieser Studie nicht best€atigt werden
konnten, resultierte die Behandlung ini 50% der F€alle in einer v€olligen bzw partialen Regression. Es sind
weitere Studien n€otig, um diese Befunde zu verifizieren und um ein Behandlungsprotokoll zu erstellen.
要約
背景 – インターロイキン (IL)-2 は抗腫瘍免疫を刺激し、さまざまな腫瘍の治療に使用されている。
仮説/目的 – ネコIL-2を局所的に発現するカナリアポックスウイルスは安全で、馬のサルコイドの治療に
使用することができる。
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摘要
背景 – 白细胞介素(IL)-2刺激抗肿瘤免疫, 并成功用于治疗不同的肿瘤。
假设/目的 – 局部表达猫IL-2的金丝雀痘病毒是安全的, 可用于治疗马结节病。
动物 – 研究纳入了20匹不同品种的马, 中位年龄为8岁 (四分位距6.0-13.3岁) , 共59种结节病。
方法 – 在这项前瞻性临床试验中, 结节病每隔七天注射两次, 用表达猫IL-2的重组金丝雀痘病毒。在治疗前
和第1、2、7和8天检测血常规 (CBC)和纤维蛋白原水平。







Contexto – A interleucina (IL)-2 estimula a imunidade antitumoral e e utilizada com sucesso no tratamento
de diferentes neoplasias.
Hipotese/Objetivos – O vırus canarypox que expressa IL-2 felina localmente e seguro e pode ser usado
para tratar sarcoides equinos.
Animais – Vinte cavalos de racas diferentes com idade mediana de oito anos (intervalo interquartil 6,0-13,3
anos) e um numero total de 59 sarcoides foram incluıdos no estudo.
Metodos – Neste ensaio clınico prospectivo, o vırus canarypox recombinante expressando IL-2 felina foi
injetado nos sarcoides duas vezes em um intervalo de sete dias. Hemogramas completos (HM) e nıveis de
fibrinogênio foram mensurados antes do tratamento e nos dias 1, 2, 7 e 8.
Resultados – Regress~ao completa foi obtida em oito cavalos (40%) e regress~ao parcial em dois cavalos
(10%). Nenhuma mudanca no tamanho do sarcoide foi observada em dois cavalos (10%) e a doenca pro-
grediu em cinco cavalos (25%). Os sarcoides de três cavalos (15%) apresentaram boa resposta inicial
seguida de crescimento do tumor. N~ao houve alterac~oes significativas no hemograma e nos nıveis de fibri-
nogênio apos qualquer injec~ao. Um cavalo apresentou febre moderada no dia seguinte de cada injec~ao,
que cedeu sem tratamento em um dia.
Conclus~oes – O tratamento de sarcoides equinos com vırus canarypox recombinante que expressa IL-2
felina parece ser uma opc~ao de terapia segura. Embora a express~ao de IL-2 apos a injec~ao do vetor e sua
atividade biologica em equinos n~ao tenham sido comprovadas neste estudo, o tratamento resultou em
regress~ao e regress~ao parcial em 50% dos casos. Mais estudos s~ao necessarios para verificar esses acha-
dos e se estabelecer um protocolo de tratamento.
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